 LEXINGTON, Mass., June 2, 2021 PRNewswire -- LogicBio Therapeutics, Inc. Nasdaq:LOGC, a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that the first patient has been dosed with LB-001, the Companys investigational single-administration gene editing therapy based on its proprietary GeneRideTM platform, in the SUNRISE Phase 12 clinical trial in pediatric patients with methylmalonic acidemia MMA. 